Investing in Ambition
With £2.5bn to invest over 10 years in venture and venture growth capital, British Patient Capital is the largest domestic investor in venture and venture growth capital in the UK. We can:
- Increase the amount of long-term investment available for innovative UK companies wanting to scale up
- Demonstrate to other investors that a long-term patient capital investment strategy can produce attractive financial returns
- Encourage more investors into making allocations to this asset class
We also work alongside institutional investors to unlock an additional £5bn of patient capital investment. This means we expect a total of £7.5bn to back the continued development of innovative firms that need access to longer-term funding.
Once we have established a strong track record, built our portfolio and proved the value of patient capital as an asset class, the intention is that British Patient Capital will be privatised.
Coronavirus and Covid-19
All of us have already been affected in some way by the spread of the Coronavirus and the Covid-19 outbreak. This is obviously a very challenging time and although the near-term outlook is uncertain, we remain committed to the continued delivery of our investment programme.
The British Patient Capital team is now working from home with internal and external meetings conducted via video conference. Fortunately, we have robust, tested and secure IT infrastructure in place and have enacted our Business Continuity Plan. All our team members are equipped with the hardware and software they need to fully carry out their roles remotely.
In short, we are very much open for business
To read the full statement from our CEO click here
Patient Capital Review
Historically, a lack of patient capital has held back many firms from scaling up and reaching their full potential. This leads to some firms being sold too early to trade buyers and failing to realise their economic promise within the UK.
As part of the Patient Capital Review the government consulted on potential barriers to accessing finance and the means to overcome them. Following the review’s conclusion in November 2017 the Chancellor announced an action plan to unlock over £20 billion to finance growth in innovative firms over 10 years. The plan included additional resources for the British Business Bank, and the creation of its commercial subsidiary, British Patient Capital.
Established in 2018, British Patient Capital builds on over a decade of investing £1bn in venture and venture growth capital funds. Several of these funds are now major names in UK venture, and many of our team bring with them the experience, knowledge and relationships gained working in predecessor programmes. These relationships and our reputation allow us to see and take advantage of opportunities others may not.